Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): A potential screening tool for the prevention of colon cancer?

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 2, 2012, Pages 337-346

  Brown, David A ^a   Hance, Kenneth W ^c   Rogers, Connie J ^c   Sansbury, Leah B ^d   Albert, Paul S ^e   Murphy, Gwen ^c   Laiyemo, Adeyinka O ^f   Wang, Zhuoqiao ^g   Cross, Amanda J ^c   Schatzkin, Arthur ^c   Danta, Mark ^a   Srasuebkul, Preeyaporn ^b   Amin, Janaki ^b   Law, Matthew ^b   Breit, Samuel N ^a   Lanza, Elaine ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Epidemiology and Genetics Research Program   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; NONSTEROID ANTIINFLAMMATORY AGENT;

ADENOMATOUS POLYP; ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COLON CANCER; COLON POLYPOSIS; COLONOSCOPY; CONCENTRATION (PARAMETERS); FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONIC NEOPLASMS; COLONIC POLYPS; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; MASS SCREENING; MICE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863140892     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0786     Document Type: Article

References (41)

1. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, et al. Mic-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9:2642-50. (Pubitemid 36842108)
2. Brown DA, Lindmark F, Stattin P, Balter K, Adami HO, Zheng SL, et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res 2009;15:6658-64.
3. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006;12:89-96. (Pubitemid 43166181)
4. Selander KS, Brown DA, Sequeiros GB, Hunter M, Desmond R, Parpala T, et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 2007;16:532-7. (Pubitemid 46548657)
5. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: Macrophage inhibitory cytokine 1 versus ca19-9. Clin Cancer Res 2006;12:442-6. (Pubitemid 43166133)
6. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004; 10:2386-92. (Pubitemid 38445697)
7. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100: 3410-5. (Pubitemid 36356597)
8. Buckhaults P, Rago C, St Croix B, Romans KE, Saha S, Zhang L, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 2001;61:6996-7001. (Pubitemid 32946484)
9. Osada M, Park HL, Park MJ, Liu JW, Wu G, Trink B, et al. A p53- type response element in the gdf15 promoter confers high specificity for p53 activation. Biochem Biophys Res Commun 2007; 354:913-8. (Pubitemid 46216219)
10. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene egr-1, which results in the up-regulation of nag-1, an antitumorigenic protein. Mol Pharmacol 2005;67:356-64. (Pubitemid 40216727)
11. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a tgf-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001;59:901-8. (Pubitemid 32274020)
12. Baek SJ, Wilson LC, Lee CH, Eling TE. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): Inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002;301: 1126-31. (Pubitemid 34595106)
13. Kim KS, Yoon JH, Kim JK, Baek SJ, Eling TE, Lee WJ, et al. Cyclooxygenase inhibitors induce apoptosis in oral cavity cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene. Biochem Biophys Res Commun 2004;325:1298-303. (Pubitemid 39535904)
14. Kim JS, Baek SJ, Sali T, Eling TE. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther 2005; 4:487-93. (Pubitemid 40443934)
15. Jang TJ, Kang HJ, Kim JR, Yang CH. Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis. Carcinogenesis 2004;25: 1853-8.
16. Zimmers TA, Gutierrez JC, Koniaris LG. Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer. J Cancer Res Clin Oncol 2010;136:571-6.
17. Eling TE, Baek SJ, Shim M, Lee CH. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 2006;39:649-55. (Pubitemid 44892888)
18. Baek SJ, Okazaki R, Lee SH, Martinez J, Kim JS, Yamaguchi K, et al. Nonsteroidal anti-inflammatorydrug-activatedgene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006;131:1553-60. (Pubitemid 44708948)
19. Schatzkin A, Lanza E, Freedman LS, Tangrea J, Cooper MR, Marshall JR, et al. The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics. Cancer Epidemiol Biomarkers Prev 1996;5:375-83. (Pubitemid 26139121)
20. Lanza E, Schatzkin A, Ballard-Barbash R, Corle D, Clifford C, Paskett E, et al. The polyp prevention trial ii: Dietary intervention program and participant baseline dietary characteristics. Cancer Epidemiol Biomarkers Prev 1996;5:385-92. (Pubitemid 26139122)
21. Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp prevention trial study group. N Engl J Med 2000; 342:1149-55. (Pubitemid 30211045)
22. Lanza E, Hartman TJ, Albert PS, Shields R, Slattery M, Caan B, et al. High dry bean intake and reduced risk of advanced colorectal adenoma recurrence among participants in the polyp prevention trial. J Nutr 2006;136:1896-903. (Pubitemid 43973595)
23. Lanza E, Schatzkin A, Daston C, Corle D, Freedman L, Ballard-Barbash R, et al. Implementation of a 4-y, high-fiber, high-fruit-and-vegetable, low-fat dietary intervention: Results of dietary changes in the polyp prevention trial. Am J Clin Nutr 2001;74:387-401. (Pubitemid 32802026)
24. Brown DA, Bauskin AR, Fairlie WD, Smith MD, Liu T, Xu N, et al. Antibody-based approach to high-volume genotyping for mic-1 polymorphism. Biotechniques 2002;33:118-20, 122, 124 passim.
25. Moore AG, Brown DA, Fairlie WD, Bauskin AR, Brown PK, Munier ML, et al. The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab 2000;85: 4781-8. (Pubitemid 32157666)
26. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): A new marker of all-cause mortality. Aging Cell 2010;9:1057-64.
27. Wakchoure S, Swain TM, Hentunen TA, Bauskin AR, Brown DA, Breit SN, et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate 2009;69:652-61.
28. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 2007;13:1333-40. (Pubitemid 350073601)
29. Tangrea JA, Albert PS, Lanza E, Woodson K, Corle D, Hasson M, et al. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control 2003;14: 403-11. (Pubitemid 36999974)
30. Breit SN, Johnen H, Cook AD, Tsai VW, Mohammad MG, Kuffner T, et al. The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 2011;29:187-95.
31. Hewett DG, Rex DK. Cap-fitted colonoscopy: a randomized, tandem colonoscopy study of adenoma miss rates. Gastrointest Endosc 2010;72:775-81.
32. Saltzman BS, Yamamoto JF, Decker R, Yokochi L, Theriault AG, Vogt TM, et al. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. Cancer Res 2008;68:1236-44. (Pubitemid 351272244)
33. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, et al. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000;275:20127-35. (Pubitemid 30441624)
34. Strelau J, Schmeer C, Peterziel H, Sackmann T, Herold-Mende C, Steiner H, et al. Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines. Cancer Lett 2008;270:30-9.
35. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF, et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002;21: 4212-9. (Pubitemid 34753827)
36. Baek SJ, Wilson LC, Eling TE. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002;23:425-34. (Pubitemid 34257622)
37. Lee SH, Kim JS, Yamaguchi K, Eling TE, Baek SJ. Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53- independent manner. Biochem Biophys Res Commun 2005;328:63-9. (Pubitemid 40164636)
38. Lee SH, Krisanapun C, Baek SJ. NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3. Carcinogenesis 2010;31:719-28.
39. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ, et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003;63: 5034-40. (Pubitemid 37022642)
40. Pang RP, Zhou JG, Zeng ZR, Li XY, Chen W, Chen MH, et al. Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through AKT/GSK3beta/NAG-1 pathway. Cancer Lett 2007;251: 268-77. (Pubitemid 46671612)
41. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003;63:4648-55. (Pubitemid 36951043)